Condition
Malignant Neoplasms of Brain
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07023640Not ApplicableRecruitingPrimary
Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
NCT00639639Phase 1CompletedPrimary
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00643097Phase 2CompletedPrimary
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00626015Phase 1CompletedPrimary
Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Showing all 4 trials